|Articles|March 15, 2020
- BioPharm International-03-15-2020
- Volume 2020 eBook
- Issue 2
Inside FDA’s New Gene and Cell Therapy Guidances
In January 2020, the agency finalized six clinical development and manufacturing guidance documents and drafted new guidance on what would qualify new gene therapies as orphan drugs.
Advertisement
Since 2017, FDA has approved four gene therapies, and regulators expect the number of gene and cell therapies under development to increase dramatically.
Article Details
BioPharm International
eBook: Regulatory Sourcebook, March 2020
March 2020
Pages: 8–11
Citation
When referring to this article, please cite it as A. Shanley, “Inside FDA’s New Gene and Cell Therapy Guidances," BioPharm International Regulatory Sourcebook eBook (March 2020).
Articles in this issue
over 5 years ago
Resources, Guidelines, and Guidance Documentsover 5 years ago
Regulatory and Standard Setting Organizationsover 5 years ago
Is There a “New Normal” for Drug Quality?over 5 years ago
Monograph Development: Why and When to Participate (eBook)over 5 years ago
A Practical Approach to Pharmacopoeia Compliance (eBook)Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5
